BioCentury
ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

February 3, 2014 8:00 AM UTC

ALK-Abello A/S (CSE:ALK-B) gained DKK5 to DKK723 last week after FDA's Allergenic Products Advisory Committee voted 6-2, with one abstention, that available data support the efficacy of Ragwitek ragweed Allergy Immunotherapy Tablet (AIT) to treat ragweed pollen-induced allergic rhinitis.

Partner Merck & Co. Inc. (NYSE:MRK) expects a decision this half. A specific action date is not disclosed...